Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
GlobalData on MSN21h
Novo Nordisk plans label expansion for Rybelsus following Phase III winThe oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Hosted on MSN6d
European Countries Are Cracking Down on Weight-Loss Drugs Like Wegovy—Could the U.S. Follow?Novo Nordisk, the pharmaceutical company behind the world’s most popular weight-loss injections, is expanding its global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback